Description of Business and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties

The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net revenue:
Product revenue (1)	$	42,959	$	30,727	$	132,945	$	88,731
Services (2)		37		308		457		808
Royalties (3)		27,083		20,218		75,326		50,951
Total net revenue	$	70,079	$	51,253	$	208,728	$	140,490

_________________________

(1)Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.

(2)Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 – Collaboration, Licensing and Other Arrangements.

(3)Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cost of goods sold and cost of revenue:
Product revenue	$	18,023	$	13,983	$	56,651	$	44,006
Services		—		271		347		698
Total cost of goods sold and cost of revenue	$	18,023	$	14,254	$	56,998	$	44,704